Dr Reddy's gets 2 observations from USFDA for Telangana API plant

Dr. Reddy's Laboratories received a Form 483 with two observations following a GMP inspection by the USFDA at its API manufacturing plant (CTO-5) in Miryalaguda, Telangana. The inspection, conducted from May 19 to May 24, 2025, identified potential violations of the Food Drug and Cosmetic Act. The company plans to address the concerns within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnPdDcN
via IFTTT